TipRanks on MSN
Celestica resumed with Hold from Buy at TD Securities
TD Securities last night downgraded Celestica (CLS) to Hold from Buy with a price target of $238, up from $130, after resuming coverage of the name. The firm is “impressed” with the company’s ...
Complete Laboratory Solutions (CLS) has announced plans to create up to 140 new impact driven roles at their Galway City ...
Celestica’s AI-driven rally continues, but valuation and concentration risks make new entries risky. Find out why CLS stock ...
Celestica stock is rated Buy as 2Q revenue jumps 21% on strong 800G data center hardware demand. See why CLS stock leads hyperscalers.
WAYNE, PA & ORLANDO, FL — Connect Life Sciences (CLS), a portfolio company of Argosy Healthcare Partners (AHP), has appointed ...
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback